Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Probing for improved potency and in vivo bioavailability of excitatory amino acid transporter subtype 1 inhibitors UCPH-101 and UCPH-102: design, synthesis and pharmacological evaluation of substituted 7-biphenyl analogs.
Erichsen MN, Hansen J, Ruiz JA, Demmer CS, Abrahamsen B, Bastlund JF, Bundgaard C, Jensen AA, Bunch L. Erichsen MN, et al. Among authors: ruiz ja. Neurochem Res. 2014 Oct;39(10):1964-79. doi: 10.1007/s11064-014-1264-8. Epub 2014 Feb 28. Neurochem Res. 2014. PMID: 24682739
New Insight into the Structure-Activity Relationships of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitors UCPH-101 and UCPH-102.
Hansen SW, Erichsen MN, Huynh TH, Ruiz JA, Haym I, Bjørn-Yoshimoto WE, Abrahamsen B, Hansen J, Storgaard M, Eriksen AL, Jensen AA, Bunch L. Hansen SW, et al. Among authors: ruiz ja. ChemMedChem. 2016 Feb 17;11(4):382-402. doi: 10.1002/cmdc.201500525. Epub 2016 Jan 12. ChemMedChem. 2016. PMID: 26757239
Bioavailability Studies and in vitro Profiling of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitor UCPH-102.
Haym I, Huynh TH, Hansen SW, Pedersen MH, Ruiz JA, Erichsen MN, Gynther M, Bjørn-Yoshimoto WE, Abrahamsen B, Bastlund JF, Bundgaard C, Eriksen AL, Jensen AA, Bunch L. Haym I, et al. Among authors: ruiz ja. ChemMedChem. 2016 Feb 17;11(4):403-19. doi: 10.1002/cmdc.201500527. Epub 2016 Jan 21. ChemMedChem. 2016. PMID: 26797816 Free article.
Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial.
Altrichter S, Giménez-Arnau AM, Bernstein JA, Metz M, Bahadori L, Bergquist M, Brooks L, Ho CN, Jain P, Lukka PB, Rodriguez-Suárez E, Walton C, Datto CJ; ARROYO Study Investigators. Altrichter S, et al. Br J Dermatol. 2024 Feb 17:ljae067. doi: 10.1093/bjd/ljae067. Online ahead of print. Br J Dermatol. 2024. PMID: 38367194
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ; HILLIER study group†. Guttman-Yassky E, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1211-e1214. doi: 10.1111/jdv.19195. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37178404 Clinical Trial. No abstract available.
160 results